Lorcaserina is an approved medication for the treatment of morbid obesity that has demonstrated its effectiveness and safety.
But in addition, this medicine could also be indicated for diabetes - at least that is what follows from a study presented at the European Association meeting for the study of diabetes by researchers at the Brigham hospital.
This is the Camellia-Timi 61 study, a clinical trial of overweight patients and obese designed to test Lorcaserina.
Although the initial objective was to see its ability to reduce the weight without cardiovascular events-results published in "The New England Journal of Medicine"-, in this meeting data has been presented that show that Lorcaserine reduced the risk of diabetes in19 percent in patients with prediabetes.The team's findings are detailed in an article published simultaneously in "The Lancet."
These findings reinforce the idea that moderate and lasting weight loss can improve cardiometabolic health
Together, says researcher Erin Bohula, “these findings reinforce the idea that moderate and lasting weight loss can improve cardiometabolic health and support the role of Lorcaserine as a complementary therapy in the control of chronic weight.
And, he adds, Benjamin Scirica, “provides another tool in the Arsenal, beyond diet and exercise, for patients who expect to reach and maintain weight loss.And, fortunately, even a relatively modest weight loss can improve the control of diabetes in people with diabetes and reduce the development of diabetes in those at risk.
«Given the global prevalence of obesity and its association with type 2 diabetes and the complications that can cause death or greatly reduce the quality of life, we need therapeutic strategies that can be added to the modification of the lifestyle to prevent and controlDiabetes, ”says Scirica.
